Nina Shah, MD, Shares Key Takeaways From Phase 2 KarMMa Trial Sub-Analysis of Ide-Cel in R/R Multiple Myeloma

Video

Nina Shah, MD, spoke about her key takeaways from a sub-analysis of the phase 2 KarMMa trial assessing correlates of complete response among those treated with idecabtagene vicleucel in relapsed/refractory multiple myeloma.

Nina Shah, MD, a hematologist oncologist from University of California, San Francisco Health, spoke with CancerNetwork® at the 2022 Tandem Meeting, aboutherkey takeaways from a sub-analysis of the phase 2 KarMMA trial (NCT03361748), assessing baseline correlates of complete response (CR) to idecabtagene vicleucel (ide-cel; Abecma) in patients with previously treated relapsed/refractory multiple myeloma. In particular, she highlights how factors such as high disease burden are associated with worse outcomes from ide-cel, and how vector copy number is associated with improved T-cell health

Transcript:

What we know from the research that we’ll be presenting this year, is that patients who ended up getting a CR had some interesting correlative outcomes from their baseline values. We [spoke] about baseline values at lymphodepletion. We know that there are various factors that yielded a significant correlation with CR in multivariate analysis, including having IgH [immunohistochemistry] heavy chain disease, serum BCMA level, and higher INR. In a positive direction, higher vector copy number was associated with their better outcomes.

These are probably things related to disease burden, in the first part where higher disease burden correlates with [worse] outcomes. On the flip side, the vector copy number probably correlates better with T-cell health. What we can think about for the patients who are going on to CAR T-cell therapy specifically with ide-cel [is that] maybe the best patients are those who are progressing but maybe not blowing up with the disease. Maybe we shouldn’t wait until line 6, 7 and 8 to use this, but rather as soon as they’re progressing on that fourth line to get them quickly in for a apheresis and then, ultimately, for their CAR T-cell therapy. That might help both aspects: decreased tumor burden going into this therapy and better T-cell health.

Reference

Shah N, Munshi N, Berdeja JG, et al. Baseline correlates of complete response to idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy in patients with relapsed and refractory multiple myeloma (RRMM): subanalysis of the KarMMa trial. Presented at the 2022 Tandem Meetings; April 22-26, 2022; Salt Lake City, UT. Poster 223.

Related Videos
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD
Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD
Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD
Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD
Related Content